Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
NCT04208958 is a completed Phase I clinical treatment trial (Single Group Assignment) that evaluated the safety and efficacy of Nivolumab + VE800 in patients with selected types of advanced or metastatic cancer, specifically melanoma, gastric/gastroesophageal junction (GEJ) adenocarcinoma, and microsatellite-stable (MSS) colorectal cancer
Primary outcome measures:
Evaluate the safety and tolerability of VE800 plus nivolumab (adverse event rates per CTCAE v5.0), and clinical activity as measured by objective response rate …